• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Why natural killer cells in triple negative breast cancer?

    2020-09-14 05:20:00
    World Journal of Clinical Oncology 2020年7期

    Mustafa Abdel-Latif,Biotechnology Program,Faculty of Pharmacy and Biotechnology,German University in Cairo,Cairo 11835,Egypt

    Rana Ahmed Youness,Pharmaceutical Biology Department,Faculty of Pharmacy and Biotechnology,German University in Cairo,Cairo 11835,Egypt

    Abstract

    Key words:Triple negative breast cancer;Natural killer cells;Immune checkpoint blockades;Programmed death-ligand 1;Cytotoxic T-lymphocyte-associated protein 4;Natural killer lectin-like group 2 member D

    INTRODUCTION

    As the leading type of cancer in women worldwide comprising 24.2% of all female cancer patients as of 2018,breast cancer (BC) is a prime target of oncological research.As of 2018,626679 deaths due to BC have been documented[1]with the actual mortality rates showing great variance according to stage of detection.This variance is demonstrated by the fact that a 99% survival rate is estimated for patients with the cancer still localized only to the breast,whereas patients in which the cancer has metastasized to more distant parts of the body show a much less encouraging survival rate of just 27%[2].

    Diversity of BC

    BC is by no means a uniform disease and is in fact represented by a number of different subtypes.Approximately 80% of BCs are estrogen receptor-positive (ER+)with the majority of these (65%) also being progesterone receptor-positive (PR+)[3,4].This means that in these subsets of BC their proliferation is stimulated by the hormones progesterone and/or estrogen due to their characteristic overexpression of these hormone receptors.As such,the typical method of therapy for ER+/PR+BC is based on targeting these receptors using blockers such as Tamoxifen?or by curtailing synthesis of the hormones themselvesviaaromatase inhibitors such as Anastrazole?and Letrozole?.About 20% of BCs are also human epidermal growth factor receptor 2(HER2) positive.The HER2 pathway is a proliferative one,meaning its overexpression results in uncontrolled cell division.The HER2+BC subtype is characterized as more aggressive in terms of tumor growth and spreading than others.However,despite its poor prognosis in relation to ER+and PR+subtypes,there remains a viable treatment strategy for HER2+BC,which relies on the targeting of HER2 using monoclonal antibodies such as trastuzumab (commercially known as Herceptin?),which abrogates the aforementioned proliferative activity of these cells and consequently attenuates malignancy,both through the direct effects of receptor blockade as well as recruitment of several immune cells through antibody-dependent cellular cytotoxicity (ADCC)[3,5].However,in roughly 10%-20% of BC cases,tumor cells are classified as negative for both hormone receptors and HER2.This case,known as triple-negative breast cancer(TNBC),is well recognized as the subtype with the poorest prognosis due to the lack of targeted therapeutic options[6,7].TNBC survival rates are comparatively lower than non-TNBC ones as demonstrated by a study published in 2018 by Gon?alves Jret al[8]that showed 5-year survival rates of 80.8% and 62.1% for non-TNBC and TNBC patients,respectively.

    TNBC patients:Worst prognosis and poorest survival rates

    As mentioned,TNBC provides the bleakest outlook of all BC subtypes.Dentet al[9]painted a picture of this in 2007 in an 8-year follow-up study of 1601 BC patients.Whilst a vast minority were TNBC patients (180;11.2%),a significantly worse prognosis was demonstrated by their higher mortality rate (42.2% in TNBCvs28% in other BC subtypes),disease recurrence (33.2%vs20.4%),with all TNBC-related deaths occurring within 10 years of initial diagnosis as opposed to regular BC mortalities stretching up to 18 years post diagnosis[9].A further study was conducted 1 year later on the same cohort investigating the metastatic effects of TNBC.Results were yet again discouraging:TNBC patients had a 23% risk factor of developing visceral metastasis within 10 years as opposed to just 9% of other BC patients[10].To this effect,the relative lack of therapeutic options for TNBC is an undoubtedly grave issue.

    Chemotherapeutic insufficiency in TNBC

    Despite its ominous implications,TNBC responds quite well to traditional chemotherapy.Response rate to neoadjuvant therapy has actually been found to be significantly higher in TNBC patients in comparison with other subtypes,with one comprehensive study by Liedtkeet al[11]on 255 TNBC patients (out of a 1118-BC patient cohort) clocking this difference at 22%vs11%.The real issue of TNBC is the poor survival rate of those who do not respond to such chemotherapies adequately,mainly due to the lack of secondary therapeutic options that would otherwise be available to PR+,ER+or HER2+patients.In an attempt to alleviate this dilemma,researchers identified the defective DNA repair pathways characteristic of TNBC as a potential target.The enzyme poly (ADP-ribose) polymerase,normally known to contribute to base-excision DNA repair,has been shown to be dysfunctional in TNBC and contributes to the genetic instability of the disease[12].As such,the poly (ADP-ribose)polymerase inhibitor iniparib has been tested in a combinatorial capacity with the chemotherapeutics gemcitabine and carboplatin.Whilst phase II trials were promising[13],phase III trials showed no considerable difference between combined therapy and sole chemotherapy[14].This yet again underlines the immense struggle to find targeted therapies in TNBC.

    WHY IMMUNOTHERAPY IN TNBC?

    However,TNBC is associated with a high degree of chromosome instability and mutation,such as that of the tumor suppressor gene TP53[15,16].Owing to this,mutant proteins produced by TNBC are hypothesized to be recognized by the immune system as unfamiliar antigens (i.e.neoantigens).This is one possible explanation to the characteristic and notable elevation of tumor-infiltrating lymphocyte (TIL) levels within the tumor microenvironments of TNBC patients,whereby lymphocytes are aggressively recruited to the site of malignancy.It is this observation of elevated TILs that prompted the reasoning that immunotherapy (i.e.stimulation of TILs or induced overexpression of neoantigens) would be an effective strategy to combat TNBC.This is further reinforced by the finding that higher TIL levels in TNBC are correlated to better prognoses amongst patients following the administration of immunestimulating chemotherapeutic agents such as anthracyclines.The heterogeneity of TNBC cells has in recent years been thoroughly examined to identify any potential candidates for targeted therapy[17].This has proven difficult,despite the identification of TNBC-specific antigens such as MAGE-A and NY-ESO-1.Usage of such antigens is merely confined to cancer “vaccines,” which enhance tumor immunogenicity by improving the action of immunotherapeutic agents such as immune checkpoint blockers (ICB)[18].

    ICB in TNBC

    The era of immuno-oncology has borne with it fresh hope for TNBC patients.As previously mentioned,the abundance of TILs in the TNBC microenvironment is indicative of immunotherapy being a promising treatment approach due to the disease’s evident immunogenicity.Naturally,evasion measures are undertaken by the disease that allows it to prosper even under the immune-heavy climate in which it grows.Upon analysis of expression patterns,the immune checkpoint ligand programmed-death ligand 1 was found to be significantly overexpressed amongst TNBC cell surfaces as one such evasion measure[19].As such,the programmed death-1/programmed-death ligand 1 axis has risen as the chief target of TNBC immunotherapies with a number of programmed-death ligand 1-directed monoclonal antibodies are currently in clinical trial phases[20].As is apparent from Table 1,the immunotherapeutic strategies of TNBC treatment are overwhelmingly biased towards ICB,with full approval still far off for most.Despite the promise of ICB in TNBC (well indicated by the progress into later trials for most monoclonal antibodies),some TNBC patients could yet find themselves short of options.

    Limitations of ICB

    Adverse inflammatory reactions:From a purely therapeutic standpoint,the effects of ICB treatment are extremely promising.Its positive response rates through the elevation of cytotoxic T-lymphocyte levels and efficacy as well as increased generation of T-helper cells are widely recognized.However,ICB by no means represents an anticancer “magic bullet” and poses issues of its own.Apart from the astronomical prices of ICB agents,a worrying problem commonly rears its head during ICB administration in the form of autoimmune events.Seeing as immune checkpoints normally serve as natural brakes to prevent prolonged or excessively severe immune responses,their blockade has predictably resulted in adverse inflammatory reactions in several cases.These responses vary greatly in terms of localization as well as severity;hypophysitis,gastroenteritis,enterocolitis,hepatitis and many other immune-mediated side effects have been observed in clinical studies,with theirintensities ranging from grade 2 (moderate) to grade 5 (life-threatening or fatal)[21].

    Table1 List of immunotherapeutic agents in various clinical trial phases and earliest expected completion dates of most significant trials[20]

    Primary and/or secondary resistance:In addition to autoimmune tendencies,another issue with ICB therapy is the emergence of resistance against it amongst treated individuals.According to clinical trial data,in addition to responders and innate nonresponders,a third category of patients who initially respond to ICB therapy but subsequently acquire resistance to it has been defined.ICB is based mainly on the regeneration of exhausted T-cells and thus largely relies on the three elements of T-cell expansion,T-cell potency,and T-cell memory formation.All three of these mechanisms have been found to be impaired in cases of ICB resistance[22].

    While unnaturally mutated neoantigens serve as the basis for immune recognition of malignant cells,the selection pressure applied by the immune system results in a remainder of cancer cells that have never innately expressed such antigens or have adapted to effectively “conceal” themselves from TILs either by shedding their neoantigens or the ability to present them through mutational loss[23].The downregulation of major histocompatibility complex (MHC) class I elements such as the β2-microglobulin domain has been documented amongst patients who acquired ICB therapy resistance.The lack of a proper antigen presentation apparatus in malignant cells in such cases greatly decreases the potential for antigen recognition and subsequent priming and clonal expansion of the T-cell pool,rendering ICB administration redundant whereby there is a numeric shortage of T-cells to be targeted[24].

    The efficacy of cytotoxic T-cells has been found to be lacking within resistant individuals.Even after antigen recognition and proper expansion/activation of the Tcell population,the tumor microenvironment is far from an ideal place for T-cells to exert their effector functions.A cocktail of immunosuppressive cytokines,alternate immune checkpoints,inhibitory receptors and immunosuppressive leukocytes are all characteristic of the tumor microenvironment and contribute to the attenuation of Tcell effector functions even after ICB therapy.Most notably,a trend of loss-of-function mutations to the genes encoding Janus kinases 1 and 2 has been highlighted amongst the tumors of resistant patients.These two proteins are components of the Janus kinase/STAT pathway,which in an immune context is crucial to the production of numerous stimulatory cytokines necessary for proper T-cell efficacy[24].

    The formation of memory antitumor CD8+ cells is one of the hallmarks of ICB therapy despite the unelucidated mechanism.Also characteristic of resistant patients is the impairment of this memory formation and consequent short-lived nature of reactivated cytotoxic T-lymphocytes[25].This could possibly be attributed to epigenetic factors that influence exhausted cells away from memory cell formation and thereby result in long-term resistance to ICB[26].

    As has been mentioned,ICB represents a new source of hope for problematic cancers such as TNBC.However,the combined prominence of autoimmunity and/or resistance in clinical studies of various malignancies indicates that TNBC will not behave any differently and will indeed display these same tendencies;once again leaving TNBC patients bereft of options.Henceforth,it is necessary to look into tertiary methods of TNBC treatment in tandem with ICB research in order to provide alternative pathways for cases in which both chemotherapy and ICB should fail.

    HUMAN IMMUNE SYSTEM

    Innate and adaptive immune arms

    The three major types of lymphocytes that comprise the mammalian immune system are T-cells,B-cells and NK cells;each playing its own indisputable role in the eternal fight between host and foreign bodies or malignancies.Whilst T-cells and B-cells are members of the adaptive immune system that is triggered by the detection of foreign antigens in the blood,NK cells belong to the innate immune system[27].This in turn implies a nonspecific mode of action whereby NK cells are not armed against particular antigens but are instead primed to fight any unnaturally altered cell.This is mainly achieved through immunoglobulin-like MHC class I-specific receptors on NK cell surfaces that phosphorylate internal inhibitory immunoreceptor tyrosine-based inhibitory motifs upon recognition of normally expressed MHC class I on functional host cells.When MHC class I is lacking or defective,as is common in virally infected and malignant cells,positive transcriptional signals are fed back to the NK cell that triggers their active cytolytic state.Other modes of activation,such as the recognition of stress-induced NK cell ligands or ADCC,also exist.It is because of this search and destroy mode of action that NK cells are often referred to as the “first line of defense”with regards to mammalian immunity[28].

    Intricate cross talk between the innate and the adaptive arms of the immune system

    The innate and adaptive immune systems are by no means secluded from one another;a constant flux of crosstalk between the two arms is characteristic of any properly functioning immune system as shown in Figure 1.An example of this is the “beacon”function of NK cells upon their encounter with malignant cells and consequent secretion of interferon-gamma.Interferon-gamma is noted for its activation of antigenpresenting cells such as macrophages and dendritic cells,which subsequently induce the effector functions of T-helper cells initiating a comprehensive cascade of adaptive immune responses[29].ADCC,where NK cells are recruited to constant regions of antibodies (derived from adaptive B-cells) coating malignant cells,is a demonstration of how the adaptive arm can potentiate the innate arm (and not only vice versa) in what has grown to be an attractive immunotherapeutic strategy[30].However,despite this evident harmonious relationship between the two arms,it has been demonstrated that,to a degree,the innate immune system can work alone in an antitumor capacity.O’Sullivanet al[31]illustrated this in a 2012 study involving groups of mice that were either:(1) Wild type;(2) Lacking an adaptive immune system;or (3) Deficient of both the adaptive and innate immune systems.Upon tumor induction,wild type mice naturally displayed the lowest rate of tumor growth.However,of the two remaining groups,mice in group 2 showed significantly more impaired tumor growth than group 3 mice,indicating a notably prominent role for innate level effector functions in antitumor immunity[31].

    EXPLOITATION OF THE INNATE IMMUNE SYSTEM:A GAP IN THE IMMUNO-ONCOLOGICAL LANDSCAPE

    Why innate-mediated immunotherapy?

    As discussed previously,the modern immuno-oncology scene is dominated by ICB,whereby our understanding of immune checkpoints has led to the commercial release of various cytotoxic T-lymphocyte-associated protein 4 and programmed death-1 blockers such as ipilimumab,pembrolizumab and nivolumab[32,33].Despite the evident focus of research on ICB and the resounding progress made over the past decade,only a small fraction (approximately 20%) of patients enjoy long-term benefits from these therapies[34].This could,in part or in full,be attributed to the previously discussed resistance mechanisms of malignancies against ICB.Most of these mechanisms,such as the shedding of the antigen-presenting apparatus on malignant cell surfaces,the upregulation of alternative immune checkpoints or the reduction of memory cell formation,are evolutionary measures directed against T-cells in the tumor microenvironment,i.e.the adaptive immune system[23,33,35].

    The incidence of resistance amongst cancer patients triggers the need to investigate on a molecular level.Whilst potential biomarkers for ICB efficacy have been investigated in a predictive sense[36],little progress has been made in elucidating the molecular bases by which acquired resistance in individual patients comes about[23].Henceforth,it is imperative that these intricacies be clarified with a view of adopting different immunotherapeutic strategies.

    Figure1 Adaptive/innate intricate relationship.

    The attractiveness of innate-mediated immunotherapy comes from the fact that,whilst not fully understood,ICB resistance mechanisms may be adaptive-specific and leave the door open for an innate approach.An example of this is the wellcharacterized shedding of human leukocyte antigen (HLA) molecules in cancer[37].This disarming of tumor cells’ antigen-presenting capability results in their significantly decreased immunogenicity with regards to the adaptive immune system.However,given NK cells’ inherent tendency to fight off cells with improper MHC function,a gateway is opened for alternative treatment for patients whose cancer has evaded ICB through this adaptive-specific mutation.It is in scenarios such as this that the innate immune system should be explored as a viable treatment option.

    With regards to autoimmunity,NK cell stimulation poses a much lower risk than their T-cell counterparts.NK cells are conventionally short-lived in their active form,indicating that therapies that rely on their stimulation and recruitment are unlikely to result in any prolonged inflammatory reaction leading to autoreactivity.Interestingly,an inverse relation was in fact proposed.This was brought about by the observation of NK cell deficiency or dysfunction in patients of autoimmune disorders[38].One hypothesis for this is an ongoing “battle” between NK cells and autoreactive T-cells,which would indeed result in NK cell clearance during T-cell overstimulation.As such,therapies that involve NK cell stimulation could and have indeed in some studies shown positive effects on autoimmunity by the induced clearance of autoreactive T-cells[39].

    NK CELLS:NATIVE SENTINELS OF THE INNATE IMMUNE ARM

    Human NK cells are the natural guards of the innate immune system.They originate from hematopoietic stem cells and undergo maturation in the bone marrow[40].NK cells are categorized as the third largest lymphocyte population[41].NK cells represent 2%-18% in human peripheral blood[41];they are also found in peripheral tissues like the liver,peritoneal cavity and placenta[42,43].NK cells are phenotypically defined by the expression of CD56 and/or CD16 and the absence of the T-cell receptor CD3[44].“Natural cytotoxicity” describes an effectively contributing phenomenon of NK cells as a first line of defense against viral infections and more in general against pathogens without prior sensitization as previously mentioned[28,45-47].NK cells are also involved in immune surveillance against tumors and prevent dissemination of metastatic tumors[48,49].These effector functions are mediated through cellular cytotoxicity (mainly through perforins and granzymes),in addition to secretion of several noncellular mediators such as chemokines and cytokines[49].NK cells cross-talking among immune cells also play a regulatory control in mediating the anti-tumor adaptive immunity of T- and B-cells that in contrast require initial priming for the expression of their activity[50-52].

    Subsets of NK cells

    Human NK cells are classified according to the relative expression of the surface markers CD16 and CD56 into two major subsets/classes:CD56 dim and CD56 bright.These subsets differ in their function,phenotype and tissue localization[53].The low density CD56 (CD56dim) subset comprises the majority (almost 90%) of peripheral blood NK cells and are characterized by their high expression of CD16,killer Ig-like receptors (KIRs) and perforins,making them more potent cytotoxic lymphocytes as illustrated in Figure 2.However,CD56brightNK cells are rarely present in peripheral blood but are predominant in lymph nodes,inflamed tissues and decidua[54,55].The latter subset has a lower cytotoxicity as it expresses low levels of perforin and KIRs[56].CD56brightNK cells are known as immunoregulatory NK cells as its functions are mainly mediated through the cytokine production such as interferon-gamma,tumor necrosis factor-α and transforming growth factor-β as shown in Figure 2[57,58].

    REPERTOIRE OF RECEPTORS ORCHESTRATING NK CELL SIGNALS

    NK cells have a unique feature of discriminating infected or malignant cells from normal “self” cellsviaa complex balance between activating and inhibitory receptorligand interactions[59].In addition,the resting inactivated NK cell surface constitutively expresses a wide range of receptors,which upon their activation by different ligands initiate several downstream signaling pathways and result in boosting NK cytotoxicity and cytokine production[60].

    Inhibitory receptors

    Upon recognition of their respective ligands,inhibitory receptors on NK cells phosphorylate associated immunoreceptor tyrosine-based inhibitory motifs,which in turn recruit the phosphatases SHP and SHIP.They dephosphorylate transcriptional signaling molecules Lck,Syk,ZAP70,Vav1 and Fyn,which results in prevention of active-form transcription patterns.This pathway,along with the simultaneous dephosphorylation of activating immunoreceptor tyrosine-based activator motif domains,ensures that NK cells are not converted into an active state upon healthy host cell encounter and thus avoids events of autoimmunity.The aforementioned MHC class I-specific receptors are commonly referred to as KIRs and are almost all inhibitory in nature.KIRs are essential for tolerance towards host cells expressing classical MHC molecules (namely HLA-A,HLA-B and HLA-C).As for nonclassical MHCs,a heterodimer of CD94 and natural killer group 2 member A is responsible for detecting molecules such as HLA-E,which despite not being an archetypal MHC can be expressed amongst healthy host cells[61].

    Activating receptors

    Natural killer lectin-like group 2,member D (NKG2D) is a hexameric transmembrane protein that acts as the principal activating receptor on NK cell surfaces.Ligands of NKG2D,termed NKG2DLs,act as triggers to the cytolytic mode of NK cells.As can be seen in Figure 3,NKG2D is associated with two DAP10 homodimers that each harbor two YINM motifs.Upon association with NKG2DLs,these motifs are phosphorylated and proceed to recruit the Grb2/Vav1/SLP-76 signaling complex and/or the p85 subunit of PI3-kinase.Taken together with the recruitment of the Syk/Zap70 complex by the alternate activating receptor Ly49D,these comprise the initial steps of three different cascades that have the downstream additive effect of amplifying both cytokine and cytotoxic molecule production within NK cells.Effectively “armed” for attack,NK cells proceed to kill their target either directly through apoptotic mechanisms such as the tumor necrosis factor,Fas/FasL,TRAIL and perforin/granzyme pathways or indirectly through stimulation of both innate and adaptive immune responseviaoverproduction of cytokines such as IL-7,IL-12,and IL-15,which serve to upregulate NKG2D expression both on fellow NK cells and adaptive CD8+ cells[61].

    Figure2 Natural killer cell subsets differ both functionally and phenotypically.

    NK cell ligands

    NKG2DLs are mainly divided into two classes:MHC class I-related proteins(comprising MIC-A and MIC-B) and UL16 binding proteins (comprising ULBPs 1-6).Given the prominence of NKG2D amongst NK cells,the most integral aspect for the effective facilitation of tumor immunosurveillance is the differential expression pattern of NKG2DLs.To this effect,NKG2DLs are commonly overexpressed amongst malignancies.Indeed,studies have shown evidence for the increased expression of MIC-A and ULBPs 1-5 in all of colorectal cancer,ovarian cancer and BC along with further evidence of MIC-B expression in BC.As prognostic factors,NKG2DLs tend to be inconsistent.An example of this being ULBP 5 overexpression indicating a positive prognosis in colorectal cancer whereas ULBPs 2 and 4 correlate with a negative prognosis in ovarian cancer.The prognostic effects of various NKG2DLs on BC were elucidated in a comprehensive 2012 study by de Kruijfet al[62]of Leiden University.The results of the study yielded the finding that high MIC-A/B and ULBP 2 expression correlated with significantly more favorable prognoses as opposed to low expression with regards to tumor size,tumor grade and relapse rates.

    NK CELLS IN CANCER

    As shown in Figure 4,NK cells are equipped with these thorough mechanisms of host and nonhost recognition and therefore are important mediators of tumor immunosurveillance and eradication.This point is underlined by the higher susceptibility to cancer yielded by mice that are NK cell-deficient in comparison with wild type mice[28]as well as the higher susceptibility of mice lacking both adaptive and innate immune components in comparison with those lacking just the adaptive arm[31].Consistent with these findings,the increased risk of cancer within humans with lower NK cell counts has been demonstrated through an 11-year follow-up study in 2000[63].This is further corroborated by the observation of NK cell cytolytic impairment in various forms of cancer,such as non-small cell lung carcinoma and BC.

    NK CELLS IN IMMUNO-ONCOLOGY

    Given their favorable characteristics in terms of resistivity and autoimmunity in comparison with adaptive methods,NK cells are a prime candidate for novel immunotherapeutic research,and their exploitation has long been appealing.Attempts to achieve this include the upregulation of stimulatory receptors,downregulation of inhibitory ones,ADCC mediation,manipulation of cytolytic pathways such as Fas/FasL and TRAIL and NK cell activation through external agents such as vaccines and chemotherapeutic drugs[38].In adoptive NK cell treatment involving external cell transfusions,it has indeed been demonstrated that increased NK cell count correlates to a favorable outcome in diseases such as non-Hodgkin lymphoma[64].With NK cells having been proven integral to anticancer immunity,recent significant attention has turned to manipulating the tumor microenvironment in an NK cell-stimulatory capacity in ways such as induced expression of activating NKG2DLs on cancer cell surfaces.

    Despite such promise,NK cell-based therapies have hardly made any clinical progress as opposed to more popular immunotherapeutic strategies such as ICB.Given ICB’s limitations,it is imperative that more attention be turned to this scope of research in the near future as a means to provide patients of aggressive and difficult-t

    少妇 在线观看| 丝袜喷水一区| 九草在线视频观看| 美女主播在线视频| 免费观看性生交大片5| 在线免费观看不下载黄p国产| 一个人免费看片子| 最近最新中文字幕大全免费视频 | 国产片内射在线| 精品99又大又爽又粗少妇毛片| 免费观看无遮挡的男女| videossex国产| 高清欧美精品videossex| 少妇人妻精品综合一区二区| 欧美日韩亚洲高清精品| 波多野结衣av一区二区av| 80岁老熟妇乱子伦牲交| 99国产精品免费福利视频| 国产精品av久久久久免费| 亚洲av欧美aⅴ国产| 哪个播放器可以免费观看大片| 搡女人真爽免费视频火全软件| 日韩三级伦理在线观看| 自拍欧美九色日韩亚洲蝌蚪91| 亚洲图色成人| 少妇 在线观看| 欧美精品亚洲一区二区| 男女边吃奶边做爰视频| h视频一区二区三区| 亚洲在久久综合| 大片免费播放器 马上看| 伦理电影大哥的女人| 热re99久久国产66热| 嫩草影院入口| 这个男人来自地球电影免费观看 | 丝袜美腿诱惑在线| 欧美成人精品欧美一级黄| 国产精品三级大全| 伊人亚洲综合成人网| 波多野结衣av一区二区av| 久久99热这里只频精品6学生| 美女脱内裤让男人舔精品视频| 精品亚洲成a人片在线观看| 美女福利国产在线| 成人黄色视频免费在线看| 久久久国产欧美日韩av| 毛片一级片免费看久久久久| 国产极品粉嫩免费观看在线| 国产男女超爽视频在线观看| 亚洲,欧美精品.| 男女午夜视频在线观看| 曰老女人黄片| 成人漫画全彩无遮挡| 制服诱惑二区| 人人妻人人澡人人爽人人夜夜| 三上悠亚av全集在线观看| 王馨瑶露胸无遮挡在线观看| 国产av国产精品国产| 国产成人精品婷婷| 精品久久蜜臀av无| 男女边摸边吃奶| 亚洲久久久国产精品| 午夜免费观看性视频| 亚洲av在线观看美女高潮| 婷婷色综合www| av国产精品久久久久影院| 女人精品久久久久毛片| 2022亚洲国产成人精品| 久久久久久久亚洲中文字幕| 在线免费观看不下载黄p国产| 综合色丁香网| 18禁裸乳无遮挡动漫免费视频| 国产精品一区二区在线观看99| 精品视频人人做人人爽| 婷婷色av中文字幕| 99久久综合免费| 久久久精品国产亚洲av高清涩受| 交换朋友夫妻互换小说| 99国产精品免费福利视频| 久久久久久久大尺度免费视频| 国产精品熟女久久久久浪| 久久久久久伊人网av| 亚洲在久久综合| 国产爽快片一区二区三区| 青青草视频在线视频观看| 成人手机av| 99国产综合亚洲精品| 婷婷成人精品国产| 午夜激情av网站| 咕卡用的链子| av国产久精品久网站免费入址| 人人妻人人添人人爽欧美一区卜| 美女主播在线视频| 免费女性裸体啪啪无遮挡网站| 亚洲久久久国产精品| 另类亚洲欧美激情| 国产xxxxx性猛交| 久久97久久精品| 久久久国产精品麻豆| 免费看不卡的av| 高清在线视频一区二区三区| 麻豆乱淫一区二区| 天天躁日日躁夜夜躁夜夜| 国产综合精华液| 两个人看的免费小视频| 成人18禁高潮啪啪吃奶动态图| 免费久久久久久久精品成人欧美视频| 在线观看三级黄色| 免费av中文字幕在线| 大片电影免费在线观看免费| 可以免费在线观看a视频的电影网站 | 国产在线视频一区二区| 18+在线观看网站| 精品国产一区二区三区久久久樱花| 在线精品无人区一区二区三| 赤兔流量卡办理| 少妇的逼水好多| 亚洲欧美精品综合一区二区三区 | 我的亚洲天堂| 亚洲av成人精品一二三区| 美女大奶头黄色视频| 亚洲人成77777在线视频| 热99久久久久精品小说推荐| 久久女婷五月综合色啪小说| 亚洲精品久久久久久婷婷小说| 久久精品aⅴ一区二区三区四区 | 美女视频免费永久观看网站| 国产精品免费视频内射| 国产精品久久久久久精品电影小说| 精品少妇内射三级| 91精品伊人久久大香线蕉| 啦啦啦中文免费视频观看日本| 久久97久久精品| av国产久精品久网站免费入址| 七月丁香在线播放| 91国产中文字幕| 欧美日韩一级在线毛片| 如日韩欧美国产精品一区二区三区| 日韩一本色道免费dvd| 欧美日韩成人在线一区二区| 久久久久久久亚洲中文字幕| 精品亚洲成国产av| 国产又爽黄色视频| 91成人精品电影| 久久精品aⅴ一区二区三区四区 | 涩涩av久久男人的天堂| videos熟女内射| 免费黄色在线免费观看| 国产精品国产三级国产专区5o| 欧美国产精品va在线观看不卡| 亚洲婷婷狠狠爱综合网| 色视频在线一区二区三区| 日韩成人av中文字幕在线观看| www.精华液| 一边亲一边摸免费视频| 一级毛片电影观看| 美女xxoo啪啪120秒动态图| 在线观看免费高清a一片| 91在线精品国自产拍蜜月| 咕卡用的链子| 精品国产国语对白av| 欧美国产精品一级二级三级| 最近最新中文字幕免费大全7| 国产精品免费大片| 91久久精品国产一区二区三区| 亚洲成人手机| 国产视频首页在线观看| 在线观看免费高清a一片| 啦啦啦啦在线视频资源| 久久精品国产亚洲av天美| 欧美97在线视频| 欧美黄色片欧美黄色片| 免费人妻精品一区二区三区视频| 七月丁香在线播放| 久久精品久久精品一区二区三区| 亚洲欧美中文字幕日韩二区| 免费黄频网站在线观看国产| 精品酒店卫生间| 精品久久久久久电影网| 青春草亚洲视频在线观看| 精品少妇久久久久久888优播| 亚洲色图综合在线观看| 亚洲av免费高清在线观看| 一二三四在线观看免费中文在| 一本大道久久a久久精品| 亚洲国产色片| 精品人妻一区二区三区麻豆| 精品国产一区二区三区久久久樱花| 精品久久蜜臀av无| 狂野欧美激情性bbbbbb| 免费在线观看完整版高清| 只有这里有精品99| 亚洲欧洲精品一区二区精品久久久 | 国产乱来视频区| 久久国产精品男人的天堂亚洲| 在线天堂最新版资源| av片东京热男人的天堂| av国产精品久久久久影院| 久热久热在线精品观看| 91精品三级在线观看| 如日韩欧美国产精品一区二区三区| 久久午夜综合久久蜜桃| 国产亚洲av片在线观看秒播厂| 亚洲人成电影观看| 女性被躁到高潮视频| 国产又色又爽无遮挡免| 日日撸夜夜添| 美女视频免费永久观看网站| 亚洲av中文av极速乱| 在线观看免费高清a一片| 久久婷婷青草| 女人精品久久久久毛片| 97精品久久久久久久久久精品| 亚洲内射少妇av| 中文精品一卡2卡3卡4更新| videosex国产| 午夜福利网站1000一区二区三区| 日本午夜av视频| 成人影院久久| 超色免费av| 精品久久蜜臀av无| 亚洲一区中文字幕在线| 黄色 视频免费看| 大香蕉久久网| 欧美bdsm另类| 少妇猛男粗大的猛烈进出视频| 中文字幕亚洲精品专区| av有码第一页| 亚洲美女视频黄频| 亚洲婷婷狠狠爱综合网| 精品亚洲成国产av| 日本-黄色视频高清免费观看| av又黄又爽大尺度在线免费看| 国产片特级美女逼逼视频| 美女午夜性视频免费| 大话2 男鬼变身卡| av一本久久久久| 黄网站色视频无遮挡免费观看| 一级毛片黄色毛片免费观看视频| 亚洲精品av麻豆狂野| 午夜福利一区二区在线看| 亚洲美女视频黄频| 久久久久久久大尺度免费视频| 母亲3免费完整高清在线观看 | 黄色 视频免费看| 午夜福利网站1000一区二区三区| 少妇猛男粗大的猛烈进出视频| 午夜免费男女啪啪视频观看| 亚洲精品乱久久久久久| 高清在线视频一区二区三区| 两性夫妻黄色片| 女性被躁到高潮视频| 久久久国产精品麻豆| 91久久精品国产一区二区三区| tube8黄色片| 精品国产乱码久久久久久小说| 一二三四在线观看免费中文在| 美女脱内裤让男人舔精品视频| 黄片播放在线免费| 午夜免费男女啪啪视频观看| 欧美中文综合在线视频| 美女午夜性视频免费| 一区二区av电影网| 在线 av 中文字幕| 久久久欧美国产精品| 国产欧美日韩一区二区三区在线| 9191精品国产免费久久| 久久人人97超碰香蕉20202| 日韩在线高清观看一区二区三区| 久久久久久久久久久久大奶| 国产麻豆69| 成人免费观看视频高清| 只有这里有精品99| 色哟哟·www| 亚洲五月色婷婷综合| 欧美成人精品欧美一级黄| 男女国产视频网站| 亚洲成人手机| 国产日韩欧美在线精品| 熟女电影av网| 亚洲内射少妇av| 下体分泌物呈黄色| 欧美在线黄色| 少妇被粗大的猛进出69影院| 中文字幕另类日韩欧美亚洲嫩草| 纵有疾风起免费观看全集完整版| 亚洲内射少妇av| 欧美成人午夜精品| 丁香六月天网| 国产av精品麻豆| 免费久久久久久久精品成人欧美视频| 美女国产高潮福利片在线看| 免费少妇av软件| 精品少妇黑人巨大在线播放| 午夜福利网站1000一区二区三区| 欧美精品国产亚洲| 69精品国产乱码久久久| 国产97色在线日韩免费| 国产免费一区二区三区四区乱码| 在线亚洲精品国产二区图片欧美| a级片在线免费高清观看视频| 母亲3免费完整高清在线观看 | 久久久国产一区二区| av电影中文网址| 成年av动漫网址| 成人免费观看视频高清| 日韩制服骚丝袜av| 啦啦啦中文免费视频观看日本| 日韩免费高清中文字幕av| 免费黄网站久久成人精品| 国产高清不卡午夜福利| 婷婷色综合大香蕉| 最近中文字幕高清免费大全6| 最近2019中文字幕mv第一页| 日本欧美视频一区| 亚洲成色77777| 色94色欧美一区二区| 大陆偷拍与自拍| 免费人妻精品一区二区三区视频| 亚洲视频免费观看视频| 性色av一级| 精品人妻在线不人妻| 91午夜精品亚洲一区二区三区| 精品久久蜜臀av无| av国产久精品久网站免费入址| 99热全是精品| 国产不卡av网站在线观看| 视频在线观看一区二区三区| www.熟女人妻精品国产| a 毛片基地| 国产淫语在线视频| 狠狠婷婷综合久久久久久88av| 日韩中文字幕视频在线看片| 热re99久久国产66热| 99九九在线精品视频| 老汉色∧v一级毛片| 少妇的逼水好多| 亚洲av中文av极速乱| av天堂久久9| 国产欧美日韩一区二区三区在线| 亚洲精品美女久久av网站| 男人操女人黄网站| 黑人欧美特级aaaaaa片| 亚洲精品第二区| 亚洲男人天堂网一区| 中文欧美无线码| 青春草亚洲视频在线观看| 在线免费观看不下载黄p国产| 男女无遮挡免费网站观看| 免费女性裸体啪啪无遮挡网站| 男女高潮啪啪啪动态图| 亚洲精品日本国产第一区| 18+在线观看网站| 国产成人精品久久二区二区91 | 久久狼人影院| 母亲3免费完整高清在线观看 | 毛片一级片免费看久久久久| 黑人巨大精品欧美一区二区蜜桃| 欧美激情 高清一区二区三区| 国产极品天堂在线| 欧美精品av麻豆av| 丰满饥渴人妻一区二区三| 久久久欧美国产精品| 一级片免费观看大全| 男女高潮啪啪啪动态图| 一级黄片播放器| 国产精品国产av在线观看| 精品人妻偷拍中文字幕| 亚洲综合色网址| 免费日韩欧美在线观看| 欧美av亚洲av综合av国产av | 美女高潮到喷水免费观看| 日韩一卡2卡3卡4卡2021年| 国产在视频线精品| 国产精品麻豆人妻色哟哟久久| 天堂中文最新版在线下载| 欧美精品av麻豆av| av女优亚洲男人天堂| 亚洲精华国产精华液的使用体验| 亚洲精品日韩在线中文字幕| 久久热在线av| 国产精品久久久久久精品古装| 十八禁网站网址无遮挡| 搡女人真爽免费视频火全软件| 春色校园在线视频观看| 欧美在线黄色| 最新的欧美精品一区二区| 搡老乐熟女国产| 天堂俺去俺来也www色官网| 国产精品二区激情视频| 99热国产这里只有精品6| 99久久综合免费| av在线老鸭窝| 精品福利永久在线观看| 久久ye,这里只有精品| 麻豆精品久久久久久蜜桃| 欧美人与善性xxx| 亚洲精品,欧美精品| 最近中文字幕高清免费大全6| 亚洲成人一二三区av| 国产伦理片在线播放av一区| 91国产中文字幕| 国产av国产精品国产| 黑人巨大精品欧美一区二区蜜桃| 精品国产乱码久久久久久男人| 最近最新中文字幕免费大全7| 国产精品熟女久久久久浪| 久久这里有精品视频免费| 男的添女的下面高潮视频| 男女高潮啪啪啪动态图| 婷婷成人精品国产| 女性生殖器流出的白浆| 哪个播放器可以免费观看大片| 亚洲欧洲精品一区二区精品久久久 | 免费看av在线观看网站| 18禁国产床啪视频网站| 中文欧美无线码| 久久影院123| 麻豆乱淫一区二区| 国产午夜精品一二区理论片| 丝袜人妻中文字幕| 色视频在线一区二区三区| 精品人妻一区二区三区麻豆| 久久精品国产亚洲av高清一级| 欧美日韩亚洲国产一区二区在线观看 | 色网站视频免费| 女人精品久久久久毛片| 国产精品嫩草影院av在线观看| 18禁国产床啪视频网站| 成人国产麻豆网| av电影中文网址| a级毛片在线看网站| 免费人妻精品一区二区三区视频| 国产片内射在线| 777久久人妻少妇嫩草av网站| 国产精品不卡视频一区二区| 国产精品国产三级专区第一集| 综合色丁香网| 国产亚洲av片在线观看秒播厂| 免费高清在线观看视频在线观看| 美女xxoo啪啪120秒动态图| 亚洲国产成人一精品久久久| 欧美日韩综合久久久久久| 免费久久久久久久精品成人欧美视频| 精品99又大又爽又粗少妇毛片| 免费大片黄手机在线观看| 极品人妻少妇av视频| 久久久久久久精品精品| 久久久久人妻精品一区果冻| 欧美 日韩 精品 国产| 99国产综合亚洲精品| 国产亚洲欧美精品永久| 亚洲三区欧美一区| 亚洲国产日韩一区二区| 国产麻豆69| 欧美日韩av久久| 91精品三级在线观看| 七月丁香在线播放| 久久久久国产精品人妻一区二区| 尾随美女入室| 免费播放大片免费观看视频在线观看| 亚洲综合精品二区| 午夜免费观看性视频| 亚洲天堂av无毛| 天天躁日日躁夜夜躁夜夜| 久久这里有精品视频免费| 国产 一区精品| 99九九在线精品视频| 精品一区二区三卡| 国产黄频视频在线观看| 99九九在线精品视频| 80岁老熟妇乱子伦牲交| 又大又黄又爽视频免费| 超碰成人久久| 亚洲,欧美,日韩| 欧美精品国产亚洲| 欧美亚洲日本最大视频资源| 你懂的网址亚洲精品在线观看| 久久久精品94久久精品| 18禁动态无遮挡网站| 制服丝袜香蕉在线| 国产综合精华液| 伊人久久国产一区二区| 亚洲激情五月婷婷啪啪| 少妇猛男粗大的猛烈进出视频| 男女无遮挡免费网站观看| 欧美日韩一级在线毛片| av女优亚洲男人天堂| www.av在线官网国产| xxx大片免费视频| 欧美亚洲日本最大视频资源| 日本-黄色视频高清免费观看| 在线观看美女被高潮喷水网站| 少妇被粗大的猛进出69影院| 啦啦啦在线观看免费高清www| 老熟女久久久| 男女下面插进去视频免费观看| 最近中文字幕高清免费大全6| 免费少妇av软件| 五月伊人婷婷丁香| 亚洲一区中文字幕在线| 九草在线视频观看| 精品久久蜜臀av无| 久久久久久久大尺度免费视频| 人成视频在线观看免费观看| 国产1区2区3区精品| 热99久久久久精品小说推荐| 美女国产视频在线观看| 青春草国产在线视频| 美女脱内裤让男人舔精品视频| 精品少妇久久久久久888优播| 亚洲国产看品久久| 欧美日韩一级在线毛片| 妹子高潮喷水视频| 亚洲av欧美aⅴ国产| 美女福利国产在线| 久久精品aⅴ一区二区三区四区 | 免费高清在线观看视频在线观看| av不卡在线播放| 亚洲久久久国产精品| 丰满乱子伦码专区| 纯流量卡能插随身wifi吗| 男女边摸边吃奶| 久久午夜福利片| 一本一本久久a久久精品综合妖精 国产伦在线观看视频一区 | 男女国产视频网站| 免费黄网站久久成人精品| 国产精品 国内视频| 亚洲色图综合在线观看| 热99久久久久精品小说推荐| 成人国产av品久久久| 亚洲中文av在线| 亚洲av电影在线观看一区二区三区| 久久国产精品男人的天堂亚洲| 亚洲精品,欧美精品| 曰老女人黄片| 欧美日韩综合久久久久久| 日本爱情动作片www.在线观看| 日韩欧美一区视频在线观看| 国产97色在线日韩免费| 亚洲伊人色综图| 少妇人妻 视频| 国产精品久久久久久久久免| av在线观看视频网站免费| 少妇熟女欧美另类| 国产成人精品无人区| 在现免费观看毛片| 国产av码专区亚洲av| 国产成人免费无遮挡视频| 99国产精品免费福利视频| 精品一区在线观看国产| 久久久久久久亚洲中文字幕| 精品一区二区三区四区五区乱码 | 亚洲精品美女久久久久99蜜臀 | 成年动漫av网址| 亚洲一级一片aⅴ在线观看| 九九爱精品视频在线观看| 麻豆av在线久日| 美国免费a级毛片| 成人亚洲精品一区在线观看| 免费观看性生交大片5| 中文字幕人妻丝袜一区二区 | 啦啦啦在线观看免费高清www| 丝袜喷水一区| 可以免费在线观看a视频的电影网站 | 国产成人av激情在线播放| 精品人妻在线不人妻| 国产男女内射视频| 久久精品熟女亚洲av麻豆精品| 久久久久国产一级毛片高清牌| 丝袜喷水一区| 亚洲成国产人片在线观看| 久久久久久久亚洲中文字幕| 国产成人免费观看mmmm| 999久久久国产精品视频| 成人手机av| 久久久精品区二区三区| 久久99一区二区三区| 欧美国产精品va在线观看不卡| 肉色欧美久久久久久久蜜桃| 国产在视频线精品| 伦理电影大哥的女人| 亚洲,一卡二卡三卡| 日韩,欧美,国产一区二区三区| 人人澡人人妻人| 国产精品不卡视频一区二区| 国产片内射在线| 秋霞伦理黄片| √禁漫天堂资源中文www| 亚洲,欧美,日韩| 美女福利国产在线| 日本免费在线观看一区| 一本大道久久a久久精品| 人体艺术视频欧美日本| 亚洲欧美清纯卡通| 国产av码专区亚洲av| 春色校园在线视频观看| 亚洲第一区二区三区不卡| 性色avwww在线观看| 欧美日韩一区二区视频在线观看视频在线| 午夜福利影视在线免费观看| 欧美xxⅹ黑人| 亚洲精品日本国产第一区| 男的添女的下面高潮视频| 男人爽女人下面视频在线观看| 久久精品国产亚洲av高清一级| 国产片特级美女逼逼视频| 国产精品 国内视频| 不卡av一区二区三区| 制服丝袜香蕉在线| 中文乱码字字幕精品一区二区三区| 中文字幕人妻丝袜制服| 女性被躁到高潮视频| 一级片免费观看大全| 亚洲一区中文字幕在线|